BSE Live
Nov 20, 16:01Prev. Close
961.20
Open Price
951.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 20, 16:01Prev. Close
963.30
Open Price
958.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
923.40 (188)
| Key Financial Ratios of Strides Pharma Science (in Rs. Cr.) | Mar 15 | Mar 14 | Dec 12 | Dec 11 | Dec 10 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 89.36 | 593.65 | 9.55 | 20.30 | 15.31 | |
| Diluted EPS (Rs.) | 88.99 | 591.14 | 5.84 | 20.13 | 15.31 | |
| Cash EPS (Rs.) | 97.55 | 597.69 | 12.77 | 23.22 | 17.92 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 247.32 | 273.80 | 233.22 | 232.82 | 243.14 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 247.32 | 273.80 | 233.22 | 232.82 | 243.14 | |
| Dividend / Share(Rs.) | 108.00 | 505.00 | 2.00 | 2.00 | 1.50 | |
| Revenue from Operations/Share (Rs.) | 155.90 | 178.60 | 121.08 | 128.40 | 87.39 | |
| PBDIT/Share (Rs.) | 39.27 | 45.22 | 36.50 | 28.86 | 29.47 | |
| PBIT/Share (Rs.) | 31.01 | 37.29 | 33.25 | 25.84 | 26.86 | |
| PBT/Share (Rs.) | 112.22 | 774.26 | 10.18 | 21.61 | 15.03 | |
| Net Profit/Share (Rs.) | 89.29 | 589.75 | 9.52 | 20.20 | 15.31 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 25.18 | 25.32 | 30.14 | 22.47 | 33.72 | |
| PBIT Margin (%) | 19.88 | 20.88 | 27.45 | 20.12 | 30.73 | |
| PBT Margin (%) | 71.98 | 433.51 | 8.41 | 16.83 | 17.19 | |
| Net Profit Margin (%) | 57.27 | 330.20 | 7.86 | 15.73 | 17.52 | |
| Return on Networth / Equity (%) | 36.10 | 215.39 | 4.08 | 8.67 | 6.29 | |
| Return on Capital Employed (%) | 31.91 | 212.25 | 3.26 | 6.60 | 3.92 | |
| Return on Assets (%) | 24.60 | 143.96 | 2.43 | 3.61 | 2.92 | |
| Total Debt/Equity (X) | 0.22 | 0.12 | 0.42 | 0.57 | 0.88 | |
| Asset Turnover Ratio (%) | 42.95 | 43.59 | 30.97 | 22.97 | 16.71 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.45 | 1.54 | 0.98 | 1.06 | 2.36 | |
| Quick Ratio (X) | 2.14 | 1.37 | 0.81 | 0.97 | 2.19 | |
| Inventory Turnover Ratio (X) | 5.98 | 7.78 | 6.82 | 5.75 | 3.90 | |
| Dividend Payout Ratio (NP) (%) | 120.85 | 85.62 | 21.07 | 9.95 | 10.35 | |
| Dividend Payout Ratio (CP) (%) | 110.61 | 84.49 | 15.71 | 8.65 | 8.84 | |
| Earnings Retention Ratio (%) | -20.85 | 14.38 | 78.93 | 90.05 | 89.65 | |
| Cash Earnings Retention Ratio (%) | -10.61 | 15.51 | 84.29 | 91.35 | 91.16 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 7,278.36 | 2,325.79 | 6,995.30 | 3,037.78 | 3,753.29 | |
| EV/Net Operating Revenue (X) | 7.83 | 2.19 | 9.82 | 4.05 | 7.44 | |
| EV/EBITDA (X) | 31.09 | 8.63 | 32.59 | 18.03 | 22.06 | |
| MarketCap/Net Operating Revenue (X) | 7.56 | 2.17 | 9.05 | 3.12 | 5.14 | |
| Retention Ratios (%) | -20.85 | 14.37 | 78.92 | 90.04 | 89.64 | |
| Price/BV (X) | 4.77 | 1.41 | 4.70 | 1.72 | 1.85 | |
| Price/Net Operating Revenue | 7.56 | 2.17 | 9.05 | 3.12 | 5.14 | |
| Earnings Yield | 0.08 | 1.52 | 0.01 | 0.05 | 0.03 |
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
09.09.2025
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
29.07.2025
Strides Pharma Consolidated June 2025 Net Sales at Rs 1,119.74 crore, up 2.96% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016